Ocugen, Inc. · NASDAQ:OCGN
Ocugen — Q2 2021 Earnings Presentation
9 slides from Ocugen's earnings presentation, Aug 6, 2021
Slide 1: Q2 2021 Results
Q2 2021 Results August 6, 2021
Slide 2: Business update; Financial performance
Business update Financial performance Q2 2021 Results August 6, 2021
Slide 3: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continu
Slide 4: Slide 4
Slide 5: COVAXIN™: Forward momentum in dynamic environment
COVAXIN™: Forward momentum in dynamic environment Canada • Expanded rights to develop, commercialize and manufacture COVAXIN™ in Canada • Regulatory review process has begun following the completion of a rolling submission to Health Canada • Established Canadian affiliate – Vaccigen – to manage pote
Slide 6: OCU400 – On track for late 2021 clinical trials
OCU400 – On track for late 2021 clinical trials A novel gene therapy product candidate with the potential to restore retinal integrity and function across a range of genetically-diverse, inherited retinal diseases Two Phase 1/2a clinical trials planned for Q4 2021 in the United States RHO NR2E3 Toxi
Slide 7: Financial update
Financial update June 30, 2021 June 30, 2020 Research and development expense (18.9)$ (1.6)$ General and administrative expense (6.8) (1.8) Other income (expense), net (0.3) (0.2) Net loss (26.0)$ (3.6)$ Net loss to common stockholders (26.0)$ (16.2)$ Net loss per share of common stock — basic and d
Slide 8: Q & A
8 Q & A
Slide 9: Thank you
Thank you x 4